Close Menu

Evogene

Evogene and Tropical Melhoramento & Genetica aim to develop non-genetically-modified nematode-resistant soybeans using CRISPR genome editing.

NEW YORK (GenomeWeb) – Israel-based plant genetics firm Evogene today reported that its second quarter revenues declined 9 percent year over year, due to a sharp drop in revenues related to share purchases.

NEW YORK (GenomeWeb) – Evogene today said that its collaboration with Bayer CropScience for wheat improvement has been amended to focus on novel genomic promoters from a prior focus on the discovery of additional genes and SNPs.

NEW YORK (GenomeWeb) – Evogene and Marrone Bio Innovations today announced a collaboration to discover new modes of biological action for insect control and to develop and commercialize new insect control products.

NEW YORK (GenomeWeb News) – Evogene today announced the closing of its US initial public offering, raising $84.8 million in gross proceeds.

NEW YORK (GenomeWeb News) – Plant genomics firm Evogene has gone public in the US through the offering of 5 million shares of common stock at an offering price of $14.75 per share, bringing in gross proceeds of $73.75 million.

NEW YORK (GenomeWeb News) – Israeli plant genomics company Evogene said in an amended registration statement filed with the US Securities and Exchange Commission on Wednesday that it aims to raise $79 million in net proceeds through its initial public offering in the US.

NEW YORK (GenomeWeb News) – Evogene and Monsanto today announced they have expanded and extended an R&D collaboration aimed at identify plant genes related to yield, environmental stress, and fertilizer utilization.

NEW YORK (GenomeWeb News) – Israeli plant genomics firm Evogene today reported a 5 percent increase in revenues for its third quarter.

NEW YORK (GenomeWeb News) – Evogene today announced that it and DuPont Pioneer have extended and expanded their multiyear research collaboration aimed at developing varieties of soybean resistant to Asian Soybean Rust, or ASR.

Pages

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.